Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
-
Publication number: 20140024625Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6?s (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: ApplicationFiled: March 12, 2013Publication date: January 23, 2014Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20140004186Abstract: Preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and at least one statin or pharmaceutically acceptable salt, hydrate, solvate, or complex thereof, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.Type: ApplicationFiled: September 8, 2011Publication date: January 2, 2014Applicant: Pronova Biopharma Norge ASInventors: Svein Olaf Hustvedt, Preben Houlberg OLesen, Gunnar Berge, Jo Erik Johnsrud Klaveness
-
Publication number: 20140004157Abstract: An object is to achieve a big effect about an agent for delaying digestion and absorption of lipid or a lipase inhibitor which is composed of specific triacylglycerol and fat-soluble and which exerts the effect more mildly with small used amount. An oil-in-water emulsion having 2 ?m or less of average particle diameter, in which a melting point of a fat composition which composes an oil phase of the emulsion is 37° C. or less and the fat composition includes 30% by weight or more of BX2 triacylglycerol (B represents Behenic acid and X represents fatty acid having 4 to 24 carbon atoms) is simultaneously ingested with ingesting fat-containing food. An amount of the BX2 triacylglycerol with respect to fat amount derived from fat-containing food ingested simultaneously is preferably 0.5 to 20% by weight.Type: ApplicationFiled: June 26, 2013Publication date: January 2, 2014Inventors: Toshiharu ARISHIMA, Makiko KOJIMA
-
Patent number: 8618168Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.Type: GrantFiled: May 21, 2010Date of Patent: December 31, 2013Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Hirosato Fujii, Motoo Yamagata
-
Publication number: 20130344012Abstract: A metathesized natural oil composition comprising (i) a mixture olefins and/or esters, or (ii) a metathesized natural oil, is disclosed. The metathesized natural oil composition has a number average molecular weight in the range from about 100 g/mol to about 150,000 g/mol, a weight average molecular weight in the range from about 1,000 g/mol to about 100,000 g/mol, a z-average molecular weight in the range from about 5,000 g/mol to about 1,000,000 g/mol, and a polydispersity index of about 1 to about 20. The metathesized natural oil composition is metathesized at least once.Type: ApplicationFiled: June 20, 2013Publication date: December 26, 2013Inventors: Steven A. Cohen, M. Michelle Morie-Bebel, Alexander D. Ilseman, Benjamin Bergmann, Stephen A. DiBiase, S. Alexander Christensen
-
Patent number: 8613912Abstract: The present invention is directed toward a series of silicone/organic polymers with tunable ascetics, solubility, film formation and performance in cosmetic formulation. These novel polymers are designed with the three different hydroxyl containing monomers in the polyester. One is a siliphillic (silicone loving) and the other a oleophillic (oil loving) and the last hydrophilic (water loving). It is critical for there to be all three types of monomers linked together in a single polymer in order to make polymers in which solubility, spreadability, surface tension and film hardness can be altered for different cosmetic applications. When these groups are present a polymer there is a wide range of variation possible, making these polymers formulator friendly.Type: GrantFiled: March 25, 2013Date of Patent: December 24, 2013Assignee: SurfaTech CorporationInventor: Thomas George O'Lenick
-
Publication number: 20130338225Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.Type: ApplicationFiled: May 24, 2013Publication date: December 19, 2013Applicant: NEW YORK UNIVERSITYInventors: Michael D. Ward, Jeffrey Rimer
-
Publication number: 20130338165Abstract: Methods of treating Parkinson's Disease comprising administering compounds that up-regulate cystine-glutamate exchange (system Xc?) and/or increase glutathione levels in the brain cells. Preferred compounds are cysteine/cystine prodrugs or N-acetyl cysteine (NAC) prodrugs.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: David A. Baker, Daniel G. Lawton, Chad Beyer, Michael Neary
-
Patent number: 8609138Abstract: Provided is a compound preparation including at least one selected from the group consisting of ?3 polyunsaturated fatty acids and pharmaceutically acceptable salts and esters thereof and at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation is in a form of a soft capsule having a capsule coating with a pH of 7.0 to 9.5. The compound preparation suppresses the decomposition of the statin compounds and/or the modification/insolubilization of the capsule coating. A medical use for the compound preparation, a method of manufacturing the compound preparation and a method of using the compound preparation are also provided.Type: GrantFiled: June 29, 2011Date of Patent: December 17, 2013Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Hirosato Fujii, Hiromitsu Ito, Motoo Yamagata
-
Publication number: 20130317103Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.Type: ApplicationFiled: February 14, 2013Publication date: November 28, 2013Applicant: Biogen Idec MA Inc.Inventor: Biogen Idec MA Inc.
-
Publication number: 20130315968Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: July 29, 2013Publication date: November 28, 2013Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Yvon Carpentier
-
Publication number: 20130317104Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).Type: ApplicationFiled: March 28, 2013Publication date: November 28, 2013Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Publication number: 20130316003Abstract: The invention features a method of treating a subject in need of treatment for multiple sclerosis. The method involves orally administering to the subject in need thereof a pharmaceutical composition in unit dosage form consisting essentially of (a) from about 120 mg to about 240 mg of dimethylfumarate formulated for delayed release, and (b) one or more pharmaceutically acceptable excipients, wherein following the orally administering of the unit dosage form monomethylfumarate appears in the plasma of the subject upon hydrolysis of dimethylfumarate and the Cmax of the monomethylfumarate in the plasma of the subject is between about 0.4 and about 2 mg/L, and wherein about 480 mg of dimethylfumarate per day is orally administered to the subject.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHÖNHARTING, Bernd W. MÜLLER, Joseph R. ROBINSON
-
Publication number: 20130315993Abstract: The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: Forward Pharma A/SInventors: Henrik Nilsson, Florian Schönharting, Bernd W. Müller, Joseph R. Robinson
-
Publication number: 20130303613Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventor: Matvey E. LUKASHEV
-
Publication number: 20130302410Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventor: Ralf GOLD
-
Publication number: 20130303614Abstract: The present invention relates to a suppressor for increase in postprandial blood glucose level, which contains an ester of EPA or DHA as an active ingredient and is characterized by being administered between meals. The present invention provides a suppressor for increase in blood glucose level which is highly safe and has desired properties including storage stability, particularly a means for preventing postprandial hyperglycemia.Type: ApplicationFiled: November 8, 2011Publication date: November 14, 2013Applicants: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hideo Kanehiro, Mariko Imai
-
Patent number: 8580235Abstract: An object of the present invention is to establish means for reliably incorporating a poorly soluble UV-absorbing agent into a hair cosmetic composition, to thereby provide a hair cosmetic composition which has excellent effect of preventing UV-hair damage and which exhibits favorable sensation in use thereof. Specifically, the object can be attained through provision of a hair cosmetic composition including the following ingredients (1) and (2): (1) a polyoxy(lower alkylene) addition compound represented by formula (I): wherein R represents a phytosterol residue or a phytostanol residue; m is a number from 0 to 100; and n is a number from 5 to 100, and (2) a UV-absorbing agent having a triazine group.Type: GrantFiled: June 19, 2009Date of Patent: November 12, 2013Assignee: Shiseido Company, Ltd.Inventors: Tomoko Watanabe, Tomoyuki Kawasoe, Takashi Teshigawara, Reiji Miyahara, Masatoshi Ochiai, Taizo Fujiyama
-
Publication number: 20130295169Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventor: Biogen Idec MA Inc.
-
Publication number: 20130296424Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial ?-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.Type: ApplicationFiled: July 5, 2013Publication date: November 7, 2013Applicant: BAYLOR RESEARCH INSTITUTEInventor: Charles R. ROE
-
Patent number: 8574609Abstract: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.Type: GrantFiled: May 2, 2011Date of Patent: November 5, 2013Inventor: John Alex Lopes
-
Publication number: 20130289110Abstract: Disclosed is a method of inducing and promoting development of beneficial gut flora in a subject and/or of reducing the frequency and duration of crying periods in a subject, the method comprises administering to the subject a lipid composition comprising a vegetable-derived fat source, wherein the fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% of total palmitic acid. The method is particularly intended for children. Specific fat sources, as well as food articles and a commercial package comprising the same are disclosed.Type: ApplicationFiled: June 28, 2013Publication date: October 31, 2013Applicant: ENZYMOTEC LTD.Inventors: Fabiana BAR-YOSEPH, Yonatan MANOR, Tzafra COHEN, Amit GOREN, Yael LIFSHITZ
-
Publication number: 20130287828Abstract: The present invention relates to a composition comprising a mixture of: hydrophobic silica aerogel particles with a N specific surface area per unit of mass (SM) ranging from 500 to 1500 m2/g and a size expressed as the mean volume diameter (D[0.5]) ranging from 1 to 1500 ?m, and at least a first and at least a second hydrocarbon-based oil chosen from branched esters, pentacrythritol esters, hydrogenated polyolefins and fatty acid triglycerides, and mixtures thereof, the first hydrocarbon-based oil being present in a content of greater than or equal to 40% by weight of the mixture of the first and second oils.Type: ApplicationFiled: December 19, 2011Publication date: October 31, 2013Applicant: L'OREALInventors: Guillaume Cassin, Sylvie Poret Fristot
-
Publication number: 20130274332Abstract: An object of the present invention is to provide an ophthalmic composition for contact lens that can inhibit bacterial adhesion to a contact lens. The ophthalmic composition for contact lens can be prepared by using a combination of (A) polyoxyethylene castor oil and (B) terpenoid.Type: ApplicationFiled: December 15, 2011Publication date: October 17, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Atsuko Nakata
-
Publication number: 20130266643Abstract: Described herein are compositions comprising glyceryl-triacetate (GTA) for use in delivering non-glucose energy deriving metabolites during physical performance, which reduce lactate production and serve as thermogenic agents.Type: ApplicationFiled: April 8, 2013Publication date: October 10, 2013Inventor: John R Moffett
-
Publication number: 20130267594Abstract: A method to inhibit tissue injury in a subject resulting from exposure to radiation is provided. The method involves administering to the subject a prolyl hydroxylase (PH) inhibitor in an amount effective to inhibit tissue injury caused by radiation exposure of the subject. The invention also involves a screen for PH inhibitors that inhibit tissue damage resulting from exposure to radiation. Compounds that inhibit the enzymatic activity of PHs are tested for their ability to protect against radiation damage.Type: ApplicationFiled: September 14, 2011Publication date: October 10, 2013Applicant: DANA-FARBER CANCER INSTITUTE INC.Inventors: Brendan D. Price, Yingli Sun
-
Publication number: 20130261180Abstract: Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaenoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].Type: ApplicationFiled: May 24, 2013Publication date: October 3, 2013Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: Peter John Gillies, Ernst John Schaefer
-
Publication number: 20130259906Abstract: A pharmaceutical controlled release composition comprising one or more fumaric acid esters.Type: ApplicationFiled: February 15, 2013Publication date: October 3, 2013Applicant: Forward Pharma A/SInventors: Henrik Nilsson, Roland Rupp
-
Patent number: 8546593Abstract: Methods of making a liquid crystal mixture essentially comprised of at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one alkali reactant. The resultant mixture includes at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one salt of said fatty acid ester or fatty acid. The resultant mixture exhibits enhanced stability and aqueous solubility of fatty acids and fatty acid esters. When medium chain fatty acid monoglycerides are used in the method, the resultant mixture exhibits antimicrobial efficacy.Type: GrantFiled: October 18, 2010Date of Patent: October 1, 2013Assignee: Copperhead Chemical Company, Inc.Inventors: Richard Peter Curtis Calvert, Charles D. Cappuccino, James David Mosbaugh, Edmund L. Phelan
-
Patent number: 8541467Abstract: The present invention refers to the use of the compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.Type: GrantFiled: August 15, 2007Date of Patent: September 24, 2013Assignee: Action Medicines, S.L.Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Publication number: 20130245116Abstract: The present disclosure provides methods and compositions for the disruption of biofilms produced by Mycobacterium. Methods and compositions related to the prevention and treatment of Mycobacterium infections in which biofilm formation is implicated are also provided.Type: ApplicationFiled: September 12, 2012Publication date: September 19, 2013Inventors: Kuni Takayama, Soofia Siddiqui, Martha M. Vestling
-
Patent number: 8536223Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.Type: GrantFiled: April 29, 2010Date of Patent: September 17, 2013Assignee: Dignity Sciences LimitedInventors: Adam Kelliher, Angus Morrison, Phil Knowles
-
Patent number: 8524773Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.Type: GrantFiled: September 12, 2012Date of Patent: September 3, 2013Assignee: Biogen Idec International GmbHInventors: Rajendra Kumar Joshi, Hans-Peter Strebel
-
Patent number: 8524772Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: GrantFiled: May 11, 2009Date of Patent: September 3, 2013Assignee: Tiara Pharmaceuticals, Inc.Inventors: Yadon Arad, Liang C. Dong
-
Publication number: 20130225682Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.Type: ApplicationFiled: April 9, 2013Publication date: August 29, 2013Applicant: ACCERA, INC.Inventor: ACCERA, INC.
-
Publication number: 20130224320Abstract: This invention relates to a process to improve the feed efficiency and carcass characteristics of an animal. The process of this invention can be used to decrease the cost of animal diets, to improve performance of animals and to improve the percentage of carcass in animals.Type: ApplicationFiled: February 23, 2012Publication date: August 29, 2013Inventor: Joan Torrent Campmany
-
Publication number: 20130216615Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.Type: ApplicationFiled: February 6, 2013Publication date: August 22, 2013Inventor: David Goldman
-
Patent number: 8507558Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial ?-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.Type: GrantFiled: August 7, 2009Date of Patent: August 13, 2013Assignee: Baylor Research InstituteInventor: Charles R. Roe
-
Publication number: 20130203701Abstract: The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules. The invention further provides kits containing these pharmaceutical compositions, methods for formulating pharmaceutical compositions containing omega-3 oil, and methods for decreasing the likelihood of developing cardiovascular disease, decreasing triglyceride or LDL cholesterol levels, decreasing pain or inflammation, treating diabetes, chronic pulmonary diseases, or irritable bowel syndrome, decreasing symptoms of an autoimmune disease or allergic conditions.Type: ApplicationFiled: September 15, 2011Publication date: August 8, 2013Applicant: Maine Natural Health, Inc.Inventor: Harry J. Leighton
-
Patent number: 8501807Abstract: Disclosed is a pentaerythritol derivative represented by the following Formula 1, which improves moisture retaining ability of the stratum corneum when applied to the skin, and shows especially high moisturizing ability even in dry conditions. wherein R is independently saturated or unsaturated C6-C18 alkyl group; m and n are the same or different integers of which m is 0 to 10 and n is 1 to 10.Type: GrantFiled: February 28, 2005Date of Patent: August 6, 2013Assignee: Amorepacific CorporationInventors: Jae Won You, Chan Woo Lee, Duck Hee Kim, Kil Joong Kim, Gae Won Nam, Byoung Seok Lee, Ih Seop Chang
-
Publication number: 20130197083Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.Type: ApplicationFiled: December 7, 2012Publication date: August 1, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130197084Abstract: The present invention includes compositions and methods for treating the effects of catabolism in a patient by providing the patient with an amount of an odd-chain fatty acid sufficient to increase the intracellular ratio of AMP to ATP and reduce the activity of AMPK.Type: ApplicationFiled: March 11, 2013Publication date: August 1, 2013Applicant: BAYLOR RESEARCH INSTITUTEInventor: BAYLOR RESEARCH INSTITUTE
-
Patent number: 8496918Abstract: The present invention is directed to a series of polymeric glyceryl esters that have two different molecular weight ester chains, one solid and one liquid, which when combined into a single molecule make a polymer that is solid, but has very unique flow properties. These materials find applications as additives to formulations in personal care products where there is a desire to have a structured film (provided by the solid fatty group) and flow properties, (provided by the liquid fatty group). These compounds by virtue of their unique structure provide outstanding skin feel.Type: GrantFiled: December 8, 2011Date of Patent: July 30, 2013Assignee: SurfaTech CorporationInventor: Thomas G. O'Lenick
-
Publication number: 20130190270Abstract: Methods to reduce damage to organelles, cells, tissues, organs and organ systems or components thereof caused by strain due to mechanical stress, including stretch stress and shear stress, are provided. The methods involve treating the organelles, cells, tissues, organs, and organs systems or components thereof (such as veins used for grafts in bypass surgery) with PX-18 and related compounds. Treatment with PX-18 and related compounds reduces damage due to stress and improves the functioning of the cells, tissues, organs or organs systems or components thereof. For example, the methods prevent the buildup of atherosclerotic plaque in transplanted (grafted) veins after coronary bypass surgery.Type: ApplicationFiled: January 23, 2013Publication date: July 25, 2013Inventor: Hans W. J. Niessen
-
Publication number: 20130190327Abstract: The invention relates to bis-fatty acid conjugates; compositions comprising an effective amount of a bis-fatty acid conjugate; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a bis-fatty acid conjugate.Type: ApplicationFiled: February 25, 2011Publication date: July 25, 2013Applicant: CATABASIS PHARMACEUTICALS INCInventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
-
Publication number: 20130184346Abstract: Provided is a diacylglycerol-containing fat or oil composition in which a precipitation of crystal is inhibited even under low temperature. The fat or oil composition comprises the following components (A) and (B): (A) a polyglycerin fatty acid ester having an average polymerization degree of glycerin of 20 or more; and (B) 20 mass % or more of diacylglycerol.Type: ApplicationFiled: September 13, 2011Publication date: July 18, 2013Applicant: KAO CORPORATIONInventors: Katsuyoshi Saito, Yuki Mitsui, Junya Moriwaki
-
Patent number: 8487001Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.Type: GrantFiled: June 11, 2010Date of Patent: July 16, 2013Assignee: ProMetic BioSciences Inc.Inventors: Lyne Gagnon, Jean Barabe, Pierre Laurin, Christopher Penney, Boulos Zacharie
-
Publication number: 20130178528Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: The Trustees of Columbia University in The City of New YorkInventors: Richard J. DECKELBAUM, Yvon CARPENTIER
-
Patent number: 8476318Abstract: The invention relates to polyethylene glycol esters and blends of the polyethylene glycol esters with polyethylene glycol ethers, together with in particular cosmetic and/or dermatological preparations containing them, methods for the production thereof and use thereof.Type: GrantFiled: April 9, 2008Date of Patent: July 2, 2013Assignee: Symrise AGInventors: Gerhard Schmaus, Sabine Lange, Rolf Ohrmann, Martina Issleib
-
Patent number: 8450089Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. R1a—O-(-A-L-)m-A-O—R1b??I, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.Type: GrantFiled: November 23, 2010Date of Patent: May 28, 2013Assignee: New York UniversityInventors: Michael D. Ward, Jeffrey D. Rimer